Company Filing History:
2 out of 26 
1 out of 2 Years Active: 2022-2025
Title: Hu Long: Innovator in Antibody Development
Introduction
Hu Long is a prominent inventor based in Sichuan, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative antibodies. With a total of 2 patents, his work focuses on advancing treatments for tumors through targeted therapies.
Latest Patents
One of Hu Long's latest patents is titled "Antibody and use thereof." This patent provides an anti-CLDN18.2 antibody or an antigen-binding fragment, along with nucleic acid molecules for encoding the antibody and fragment. The antibody demonstrates high specificity and affinity to CLDN18.2, effectively binding to and mediating the killing of CLDN18.2 expressing cells. Additionally, it includes a pharmaceutical composition comprising the antibody for use in the prevention and treatment of tumors. Another notable patent is for "Recombinant bispecific antibodies to PD-L1 and CTLA-4." This invention includes a recombinant bispecific antibody against CTLA-4 and PD-L1, along with methods for preparing the antibody and its pharmaceutical compositions.
Career Highlights
Hu Long has worked with notable companies in the biopharmaceutical sector, including Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. and Klus Pharma Inc. His experience in these organizations has contributed to his expertise in antibody development and therapeutic applications.
Collaborations
Throughout his career, Hu Long has collaborated with esteemed colleagues such as Dengnian Liu and Liang Xiao. These partnerships have fostered innovation and advancement in his research endeavors.
Conclusion
Hu Long's contributions to the field of biopharmaceuticals, particularly in antibody development, highlight his role as an influential inventor. His patents reflect a commitment to improving cancer treatment options through innovative therapies.